Skip to content
10-K

Annual Report

CIDARA THERAPEUTICS, INC.

0001610618-25-000017

← back to feed
Filed
Mar 6, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 27, 2025 10.95M sh
Shares Diluted FY 2024 · Dec 31, 2024 6.35M sh
Shares Diluted restated FY 2024 · Dec 31, 2023 4.37M sh
Capex FY 2024 · Dec 31, 2024 $129K
Capex FY 2024 · Dec 31, 2023 $505K
Operating Cash Flow FY 2024 · Dec 31, 2024 −$176.53M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$22.43M
Cash And Equivalents FY 2024 · Dec 31, 2024 $189.83M
Cash And Equivalents FY 2024 · Dec 31, 2023 $35.78M
Stockholders Equity FY 2024 · Dec 31, 2024 $163.31M
Stockholders Equity FY 2024 · Dec 31, 2023 −$8.21M
Stockholders Equity restated FY 2024 · Dec 31, 2022 −$14.44M
Current Liabilities FY 2024 · Dec 31, 2024 $49.55M
Current Liabilities FY 2024 · Dec 31, 2023 $67.42M
Total Liabilities FY 2024 · Dec 31, 2024 $51.49M
Total Liabilities FY 2024 · Dec 31, 2023 $75.24M
Current Assets FY 2024 · Dec 31, 2024 $210.74M
Current Assets FY 2024 · Dec 31, 2023 $60.86M
Total Assets FY 2024 · Dec 31, 2024 $214.8M
Total Assets FY 2024 · Dec 31, 2023 $67.03M
Eps Diluted FY 2024 · Dec 31, 2024 −$26.75
Eps Diluted restated FY 2024 · Dec 31, 2023 −$5.25
Eps Basic FY 2024 · Dec 31, 2024 −$26.75
Eps Basic restated FY 2024 · Dec 31, 2023 −$5.25
Rd Expense FY 2024 · Dec 31, 2024 $71.88M
Rd Expense restated FY 2024 · Dec 31, 2023 $36.76M
Net Income FY 2024 · Dec 31, 2024 −$169.83M
Net Income FY 2024 · Dec 31, 2023 −$22.93M
Operating Income FY 2024 · Dec 31, 2024 −$176.1M
Operating Income restated FY 2024 · Dec 31, 2023 −$27.06M